Trial Profile
Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2021
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 10 May 2021 Results of pooled analysis assessing clinical pharmacokinetics of oral Semaglutide published in the Clinical Pharmacokinetics
- 06 Apr 2018 Results published in the Clinical Pharmacokinetics
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes